Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
Key facts
- Who runs it
- ModernaTX, Inc.
- Where
- Anderson, Beachwood, Dallas, East Greenwich, Meridian, Omaha, Rockville, San Bernardino, Savannah, and Suffolk, United StatesSee the 10 sitesAlso in 1 other country, 25 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 4,050 people enrolled
- Started
- 23 Mar 2026
- Expected to end
- 28 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- mRNA-1018-H5
- Placebo
- Record updated
- 11 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Healthy as determined by medical evaluation including medical history; and physical examination. Participants with clinically stable chronic medical conditions are permitted
- Participants who are assigned female at birth or could become pregnant are eligible to participate if the participant is not pregnant or breast/chest feeding, and one of the following conditions applies:; Is a person of nonchildbearing potential (PONCBP) OR; Is a person of childbearing potential (POCBP); A POCBP must have a negative highly sensitive pregnancy test at Screening and on the day of the first dose of study intervention
Who cannot take part
- Participant is acutely ill or febrile (body temperature ≥ 38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1
- Treated with antiviral therapies for influenza (eg, Tamiflu, Xofluza) within 28 days prior to Day 1
- Prior receipt of a pandemic influenza vaccine or participation in any pandemic influenza vaccine clinical study, including the mRNA-1018-P101 study
- Participant has received systemic immunosuppressants including long-acting biological therapies that affect immune responses (eg, infliximab, methotrexate, omalizumab, etc.), within 180 days prior to Screening or plans to do so at any time during participation in the study
- Participant has received corticosteroids at ≥10 mg/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 (Baseline) or is anticipating the need for corticosteroids at any time during the study
- Participants has received any licensed vaccine authorized or approved by local health agency including mRNA vaccine ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 21 days after the study intervention
- Participant has participated in an interventional clinical study within 90 days prior to the Screening visit based on the medical history interview or plans to do so while participating in this study; Note: Other inclusion/exclusion criteria may apply
- History of myocarditis, pericarditis, or myopericarditis
- History of Guillain-Barre syndrome
- Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, asplenia, or recurrent severe infections disease
- Any medical, psychiatric, or occupational condition, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with adherence to study procedures or the interpretation of study results
Where in United States
Also in 1 other country, 25 sites
- Velocity Clinical Research, AndersonAnderson, United States
- Velocity Clinical Research, ClevelandBeachwood, United States
- Velocity Clinical Research, DallasDallas, United States
- Velocity Clinical Research, ProvidenceEast Greenwich, United States
- Velocity Clinical Research, BoiseMeridian, United States
- Velocity Clinical Research - OmahaOmaha, United States
- Velocity Clinical Research, RockvilleRockville, United States
- Velocity Clinical Research, San BernardinoSan Bernardino, United States
- Velocity Clinical Research - SavannahSavannah, United States
- Velocity Clinical Research, SuffolkSuffolk, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
The 2 groups in the trial
- mRNA-1018-H5 VaccineTreatment being tested
Participants will receive mRNA-1018-H5 vaccine by intramuscular (IM) injection on Day 1 and Day 22.
Treatment: mRNA-1018-H5
- PlaceboPlacebo, for comparison
Participants will receive placebo matched to mRNA-1018-H5 vaccine by IM injection on Day 1 and Day 22.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of mRNA-1018-H5 Pandemic Influenza Vaccine in Adults ≥18 Years of Age
- Record updated
- 11 August 2026